Europe Drug of Abuse Testing Market 2013–2023 | bioMérieux, Bio-Rad Laboratories, Abbott, Quest Diagnostics, Danaher Corporation, Psychemedics Corporation

The European DOA testing market is forecasted to reach $3.0 billion by 2023. Growing alcohol consumption, rising drug trafficking, and increasing government initiatives that aim at increasing interdiction capacities and strengthening law enforcement in the region are some notable factors supporting the demand for DOA testing products and services in the region.

Download free report sample at: https://www.psmarketresearch.com/market-analysis/europe-doa-testing-market/report-sample

*Market players are expanding their portfolio through new product launches

Companies operating in the European DOA testing market are enhancing their product portfolio through new launches. For instance, in October 2018, ACM Global Laboratories announced the release of its therapeutic service offering, Smarter Testing for infectious disease, to address the demand for drug testing in clinical trials.

In November 2017, Thermo Fisher Scientific Inc. announced the launch of Thermo Scientific TruNarc handheld narcotics analyzer. This narcotic analyzer can detect Carfentanil, a fentanyl analog, which is 10,000 times more powerful than morphine.

Siemens AG, Merck KGaA, Drägerwerk AG & Co. KGaA, bioMérieux S.A., F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories Inc., Abbott Laboratories, Quest Diagnostics Inc., Danaher Corporation, Bioventix Plc, Express Diagnostics Int'l Inc., Psychemedics Corporation, and Lipomed AG are other key players present in the European DOA testing market.

Pre-Purchase Inquiry at: https://www.psmarketresearch.com/send-enquiry?enquiry-url=europe-doa-testing-market

*The U.K. is predicted to be the fastest growing DOA testing market in Europe

The U.K. DOA testing market is expected to observe the fastest growth, at a CAGR of 11.0% during the forecast period, mainly due to the increasing availability and consumption of illicit drugs in the country. According to the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), in 2017, the prevalence of cannabis use was the highest in the U.K. among all European countries, with drug consumption reported approximately 11.3% in young adults aged 16–34 years. Furthermore, the U.K. government is taking initiatives to address the healthcare challenges in the country by making investments in innovative projects for drug users to overcome drug abuse and addiction.

Browse report at: https://www.psmarketresearch.com/market-analysis/europe-doa-testing-market

EUROPE DOA TESTING MARKET SEGMENTATION
By Offering
• Products
o Consumables
 Rapid test kits
 Assay kits and reagents
 Others
o Equipment
 Immunoassay analyzers
 Chromatography instruments
 Breath analyzers
• Services
By Sample Type
• Urine
• Saliva
• Hair
• Others
By Distribution Channel
• Indirect
• Direct
By End User
• Hospitals
• Laboratories
• Workplace
• At-Home
• Others

About P&S Intelligence

P&S Intelligence is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.

Contact:
P&S Intelligence
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com

This release was published on openPR.